- Email: [email protected]
Thursday, May 19: Plenary Session
ABSTRACTS
Society of Biological Psychiatry 2005 Annual Meeting THURSDAY, MAY 19 PLENARY SESSION Pathophyiology Thursday, May 19, 8:30 AM - 10:30 AM Location: Grand Ballroom Chair: David A. Lewis The Plenary Sessions have been arranged to emphasize the various components of the theme of the meeting “Pathogenesis and Prevention of Major Mental Disorders”. The major disorders of dementia, schizophrenia, mood and anxiety, and neurodevelopment are refracted through the lens of disease pathogenesis, pathophysiology and therapeutics. Today’s Plenary Session examines these four disorders in terms of their pathophysiologic mechanisms and phenomenologic expression.
1. Deciphering the Molecular Basis of Alzheimer's Disease Predicts Novel Therapies Dennis J. Selkoe Department of Neurology, Harvard Medical School, Boston, MA Dennis J. Selkoe, MD, the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and Brigham and Women's Hospital, has devoted his career to the study of Alzheimer's disease (AD), Parkinson’s disease and related basic biological questions. A graduate of Columbia University and the University of Virginia School of Medicine. he trained at the National Institutes of Health, the Harvard/Longwood Neurology Program and in the Department of Neuroscience, HMS. Selkoe originally developed a method for isolating the neurofibrillary tangles that are a hallmark of AD and discovered their unusual properties. Subsequently, he conducted extensive experiments on amyloid ß-protein (Aß) and its precursor and helped formulate a theory of AD causation, (the “amyloid hypothesis”). Selkoe and colleagues discovered that Aß is produced by normal cells throughout life, leading to the use of cultured cells to study how Aß is formed and identify Aß inhibitors. The lab showed that mutations in APP and presenilin cause AD by increasing Aß production. Selkoe and collaborators conducted ground-breaking experiments identifying presenilin as the active site of g-secretase, an unprecedented intramembrane aspartyl protese that cleaves APP, Notch and other proteins. These advances have led to his receipt of the Potamkin Prize (shared with George G. Glenner), the A.H. Heineken Prize for Medicine, and the Metropolitan Life Award for Medial Research, among others. Selkoe was the principal founding scientist of Athena Neurosciences, now Elan, plc. He has served on numerous editorial boards, the Neuroscience Review Committee of HHMI, and the National Advisory Council on Aging. Supported by NIH, Alzheimer's Association, and other
2. Glutamate and Dopamine Crosstalk in Schizophrenia: Insight from Imaging Studies Marc Laruelle Columbia University, New York, NY Marc Laruelle is Associate Professor of Psychiatry and Radiology at Columbia University and Director of the Division for Functional Brain Mapping at the New York State Psychiatric Institute. Dr. Laruelle obtained his medical degree and completed his Neuropsychiatry residency training at the Université Catholique de Louvain in Belgium in 1988. He completed a fellowship at NIMH under Daniel Weinberger, M.D. in 1990 and was Assistant Professor in Psychiatry at Yale School of Medicine from 1992 to 1996. He joined the faculty at Columbia University in 1996 to establish a brain imaging group focusing on
0006-3223/05/$30.00 doi:10.1016/j.biopsych.2005.03.005
neurochemistry and neuropharmacology. Dr. Laruelle specializes in imaging neurotransmission using Positron Emission Tomography, particularly the serotonin and dopamine systems. Much of his research has focused on the role of dopamine and serotonin in schizophrenia and substance abuse. In addition, he has a special interest in the use of neuroreceptor imaging techniques to measure synaptic concentration of neurotransmitters, a technique that he contributed to pioneer. Additional areas of interest include development of new PET radioligands and the use of PET in drug development. Dr. Laruelle has received numerous awards for his work devoted to schizophrenia research, including, in 1996, the Paul Janssen Award for schizophrenia research and, in 2000, the Joel Elkes International Award from the American College of Neuropsychopharmacology. He has published more than 100 papers and book chapters.
3. The Persistent Neurobiological Consequences of Early Life Abuse or Neglect: Implications for the Pathophysiology and Treatment of Mood Disorders Charles B. Nemeroff Psychiatry and Behavioral Science, Emory University School of Medicine, Atlanta, GA Charles B. Nemeroff, MD, PhD is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine. He received both his PhD and MD degrees from the University of North Carolina, Chapel Hill and completed residency training at Duke University in 1985. He was a Professor in the Departments of Psychiatry and Pharmacology at Duke University, relocating to Atlanta in 1991 to assume his current position. His research has concentrated on the biological basis of the major neuropsychiatric disorders, including affective disorders, schizophrenia, and anxiety disorders. He serves as Editor-in-Chief of Neuropsychopharmacology and has published more than 750 research reports and reviews. He is currently the recipient of several research grants from the NIH, including a Conte Center for the Neurobiology of Major Mental Disorders.
4. Neurobiological and Immunological Factors in Autism David G. Amaral University of California, Davis, San Francisco, CA David Amaral joined the University of California, Davis in 1995 as a Professor in the Department of Psychiatry and Behavioral Sciences and the Center for Neuroscience. He is also a staff scientist at the California National Primate Research Center. Dr. Amaral was named the Beneto Foundation Chair and Research Director of the M.I.N.D. (Medical Investigations of Neurodevelopmental Disorders) Institute in 1998. The M.I.N.D. Institute is dedicated to understanding the biological bases of autism and other neurodevelopmental disorders with the goal of prevention and better treatment. Dr. Amaral’s laboratory pursues research programs dealing with the neurobiology of primate social behavior and with the development and neuroanatomical organization of the primate and human amygdala and hippocampal formation. His research now also includes postmortem studies of the autistic brain and magnetic resonance imaging studies of children with autism spectrum disorders. At the M.I.N.D. Institute, he is coordinating a multidisciplinary Autism Phenotyping Project with the goal of defining distinct subtypes of autism. Dr. Amaral began his career in neuroscience at Northwestern University. He then undertook a joint Ph.D. program in the Center for Brain Research and the Department of Psychology at the University of Rochester. He completed a postdoctoral research program at the Department
BIOL PSYCHIATRY 2005;57:1S-212S © 2005 Society of Biological Psychiatry
2S BIOL PSYCHIATRY 2005;57:1S-212S
www.elsevier.com/locate/biopsych
Thursday Abstracts
Thursday Abstracts
BIOL PSYCHIATRY 2005;57:1S-212S 3S
www.elsevier.com/locate/biopsych
4S BIOL PSYCHIATRY 2005;57:1S-212S
www.elsevier.com/locate/biopsych
Thursday Abstracts
Thursday Abstracts
BIOL PSYCHIATRY 2005;57:1S-212S 5S
www.elsevier.com/locate/biopsych
6S BIOL PSYCHIATRY 2005;57:1S-212S
www.elsevier.com/locate/biopsych
Thursday Abstracts
Thursday Abstracts
BIOL PSYCHIATRY 2005;57:1S-212S 7S
www.elsevier.com/locate/biopsych
8S BIOL PSYCHIATRY 2005;57:1S-212S
www.elsevier.com/locate/biopsych
Thursday Abstracts
Thursday Abstracts
BIOL PSYCHIATRY 2005;57:1S-212S 9S
www.elsevier.com/locate/biopsych
Society of Biological Psychiatry 2005 Annual Meeting THURSDAY, MAY 19 PLENARY SESSION Pathophyiology Thursday, May 19, 8:30 AM - 10:30 AM Location: Grand Ballroom Chair: David A. Lewis The Plenary Sessions have been arranged to emphasize the various components of the theme of the meeting “Pathogenesis and Prevention of Major Mental Disorders”. The major disorders of dementia, schizophrenia, mood and anxiety, and neurodevelopment are refracted through the lens of disease pathogenesis, pathophysiology and therapeutics. Today’s Plenary Session examines these four disorders in terms of their pathophysiologic mechanisms and phenomenologic expression.
1. Deciphering the Molecular Basis of Alzheimer's Disease Predicts Novel Therapies Dennis J. Selkoe Department of Neurology, Harvard Medical School, Boston, MA Dennis J. Selkoe, MD, the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and Brigham and Women's Hospital, has devoted his career to the study of Alzheimer's disease (AD), Parkinson’s disease and related basic biological questions. A graduate of Columbia University and the University of Virginia School of Medicine. he trained at the National Institutes of Health, the Harvard/Longwood Neurology Program and in the Department of Neuroscience, HMS. Selkoe originally developed a method for isolating the neurofibrillary tangles that are a hallmark of AD and discovered their unusual properties. Subsequently, he conducted extensive experiments on amyloid ß-protein (Aß) and its precursor and helped formulate a theory of AD causation, (the “amyloid hypothesis”). Selkoe and colleagues discovered that Aß is produced by normal cells throughout life, leading to the use of cultured cells to study how Aß is formed and identify Aß inhibitors. The lab showed that mutations in APP and presenilin cause AD by increasing Aß production. Selkoe and collaborators conducted ground-breaking experiments identifying presenilin as the active site of g-secretase, an unprecedented intramembrane aspartyl protese that cleaves APP, Notch and other proteins. These advances have led to his receipt of the Potamkin Prize (shared with George G. Glenner), the A.H. Heineken Prize for Medicine, and the Metropolitan Life Award for Medial Research, among others. Selkoe was the principal founding scientist of Athena Neurosciences, now Elan, plc. He has served on numerous editorial boards, the Neuroscience Review Committee of HHMI, and the National Advisory Council on Aging. Supported by NIH, Alzheimer's Association, and other
2. Glutamate and Dopamine Crosstalk in Schizophrenia: Insight from Imaging Studies Marc Laruelle Columbia University, New York, NY Marc Laruelle is Associate Professor of Psychiatry and Radiology at Columbia University and Director of the Division for Functional Brain Mapping at the New York State Psychiatric Institute. Dr. Laruelle obtained his medical degree and completed his Neuropsychiatry residency training at the Université Catholique de Louvain in Belgium in 1988. He completed a fellowship at NIMH under Daniel Weinberger, M.D. in 1990 and was Assistant Professor in Psychiatry at Yale School of Medicine from 1992 to 1996. He joined the faculty at Columbia University in 1996 to establish a brain imaging group focusing on
0006-3223/05/$30.00 doi:10.1016/j.biopsych.2005.03.005
neurochemistry and neuropharmacology. Dr. Laruelle specializes in imaging neurotransmission using Positron Emission Tomography, particularly the serotonin and dopamine systems. Much of his research has focused on the role of dopamine and serotonin in schizophrenia and substance abuse. In addition, he has a special interest in the use of neuroreceptor imaging techniques to measure synaptic concentration of neurotransmitters, a technique that he contributed to pioneer. Additional areas of interest include development of new PET radioligands and the use of PET in drug development. Dr. Laruelle has received numerous awards for his work devoted to schizophrenia research, including, in 1996, the Paul Janssen Award for schizophrenia research and, in 2000, the Joel Elkes International Award from the American College of Neuropsychopharmacology. He has published more than 100 papers and book chapters.
3. The Persistent Neurobiological Consequences of Early Life Abuse or Neglect: Implications for the Pathophysiology and Treatment of Mood Disorders Charles B. Nemeroff Psychiatry and Behavioral Science, Emory University School of Medicine, Atlanta, GA Charles B. Nemeroff, MD, PhD is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine. He received both his PhD and MD degrees from the University of North Carolina, Chapel Hill and completed residency training at Duke University in 1985. He was a Professor in the Departments of Psychiatry and Pharmacology at Duke University, relocating to Atlanta in 1991 to assume his current position. His research has concentrated on the biological basis of the major neuropsychiatric disorders, including affective disorders, schizophrenia, and anxiety disorders. He serves as Editor-in-Chief of Neuropsychopharmacology and has published more than 750 research reports and reviews. He is currently the recipient of several research grants from the NIH, including a Conte Center for the Neurobiology of Major Mental Disorders.
4. Neurobiological and Immunological Factors in Autism David G. Amaral University of California, Davis, San Francisco, CA David Amaral joined the University of California, Davis in 1995 as a Professor in the Department of Psychiatry and Behavioral Sciences and the Center for Neuroscience. He is also a staff scientist at the California National Primate Research Center. Dr. Amaral was named the Beneto Foundation Chair and Research Director of the M.I.N.D. (Medical Investigations of Neurodevelopmental Disorders) Institute in 1998. The M.I.N.D. Institute is dedicated to understanding the biological bases of autism and other neurodevelopmental disorders with the goal of prevention and better treatment. Dr. Amaral’s laboratory pursues research programs dealing with the neurobiology of primate social behavior and with the development and neuroanatomical organization of the primate and human amygdala and hippocampal formation. His research now also includes postmortem studies of the autistic brain and magnetic resonance imaging studies of children with autism spectrum disorders. At the M.I.N.D. Institute, he is coordinating a multidisciplinary Autism Phenotyping Project with the goal of defining distinct subtypes of autism. Dr. Amaral began his career in neuroscience at Northwestern University. He then undertook a joint Ph.D. program in the Center for Brain Research and the Department of Psychology at the University of Rochester. He completed a postdoctoral research program at the Department
BIOL PSYCHIATRY 2005;57:1S-212S © 2005 Society of Biological Psychiatry
2S BIOL PSYCHIATRY 2005;57:1S-212S
www.elsevier.com/locate/biopsych
Thursday Abstracts
Thursday Abstracts
BIOL PSYCHIATRY 2005;57:1S-212S 3S
www.elsevier.com/locate/biopsych
4S BIOL PSYCHIATRY 2005;57:1S-212S
www.elsevier.com/locate/biopsych
Thursday Abstracts
Thursday Abstracts
BIOL PSYCHIATRY 2005;57:1S-212S 5S
www.elsevier.com/locate/biopsych
6S BIOL PSYCHIATRY 2005;57:1S-212S
www.elsevier.com/locate/biopsych
Thursday Abstracts
Thursday Abstracts
BIOL PSYCHIATRY 2005;57:1S-212S 7S
www.elsevier.com/locate/biopsych
8S BIOL PSYCHIATRY 2005;57:1S-212S
www.elsevier.com/locate/biopsych
Thursday Abstracts
Thursday Abstracts
BIOL PSYCHIATRY 2005;57:1S-212S 9S
www.elsevier.com/locate/biopsych